CAR-T Cellular Therapy Development
CAR-T Cellular Therapy Solutions
From optimizing CAR-T cell design and evaluating pre-clinical models to discovering response biomarkers and mechanisms of action, together we can advance the field of cellular therapy and improve the human condition.
- Optimize CAR-T cell method development
- Measure metabolic fitness and persistence
- Create manufacturing acceptance criteria
- Monitor post-infusion exhaustion and toxicity
- Explore the response of the tumor microenvironment to CAR-T cells in solid tumors
- Measure changes in the solid tumor microenvironment
- Quantify CAR-T cell exhaustion
- Understand mechanisms of immune cell exhaustion
- Discover biomarkers for exhaustion
- Develop treatments to prevent or reverse immune cell exhaustion
- Spatially evaluate pre-clinical solid tumor models
- Visualize CAR-T cell trafficking within the tumor microenvironment
- Discover biomarkers for responders/non-responders
Immune Monitoring for Advanced Cell Therapy Trials in Transplantation: Which Assays and When?
A number of immune regulatory cellular therapies, including regulatory T cells and mesenchymal stromal cells, have emerged as novel alternative therapies for the control of transplant alloresponses. Clinical studies have demonstrated their feasibility and safety, however developing our understanding of the impact of cellular therapeutics in vivo requires advanced immune monitoring strategies.
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
High expression levels of human epidermal growth factor receptor 2 (HER2) have been associated with poor prognosis in patients with pancreatic adenocarcinoma (PDAC). However, HER2-targeting immunotherapies have been unsuccessful to date.
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.
The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient’s leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect production of chimeric antigen receptor (CAR) T cells, such as myeloid cells.